Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kao高, Wan-Chen婉真
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)	Recruiting	3	756	Europe, US, RoW	Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab	Shanghai Junshi Bioscience Co., Ltd.	Limited-stage Small Cell Lung Cancer (LS-SCLC)	07/27	07/29
楊, Chih-Hsin 志新 Yang
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)	Recruiting	3	756	Europe, US, RoW	Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab	Shanghai Junshi Bioscience Co., Ltd.	Limited-stage Small Cell Lung Cancer (LS-SCLC)	07/27	07/29